MDGEF (Medigene AG) Additional Paid-In Capital : $517.30 Mil(As of Jun. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Medigene AG Additional Paid-In Capital?

Medigene AG's quarterly additional paid-in capital increased from Jun. 2023 ($520.16 Mil) to Dec. 2023 ($523.71 Mil) but then stayed the same from Dec. 2023 ($523.71 Mil) to Jun. 2024 ($517.30 Mil).

Medigene AG's annual additional paid-in capital declined from Dec. 2021 ($541.91 Mil) to Dec. 2022 ($508.41 Mil) but then increased from Dec. 2022 ($508.41 Mil) to Dec. 2023 ($523.71 Mil).

Medigene AG Additional Paid-In Capital Historical Data

The historical data trend for Medigene AG's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medigene AG Additional Paid-In Capital Chart

Medigene AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

531.42

582.65

541.91

508.41

523.71

Medigene AG Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Additional Paid-In Capital	Get a 7-Day Free Trial															507.15	508.41	520.16	523.71	517.30

Medigene AG Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Medigene AG Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Medigene AG's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Medigene AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medigene AG (OTCPK:MDGEF) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

0QGJ:UK MDG1:Germany MDG2:Austria

Address

Lochhamer Strasse 11, Martinsried, Planegg, BY, DEU, 82152

Website

https://www.medigene.com

Medigene AG is an immuno-oncology biotechnology company. focused on developing differentiated T Cell Receptor engineered T cell (TCR-T) therapies for the treatment of multiple solid tumor indications with a high unmet medical need. The operating segments of the organization are Immunotherapies and Other products. Immunotherapies consist of T-cell receptor-based adoptive T-cell therapy and DC vaccines. The group operates in the United States, Germany, and Asia, of which the majority of the revenue is derived from operations in Germany.